Sutro Biopharma, Inc. (STRO) News
Filter STRO News Items
STRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STRO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest STRO News From Around the Web
Below are the latest news stories about SUTRO BIOPHARMA INC that investors may wish to consider to help them evaluate STRO as an investment opportunity.
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA. The presentation will be accessible through the News & Ev |
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scaleSOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin (luvelta), Sutro’s Tubulin FRα-targeting antibody-drug conjugate (ADC) designed to treat a broad range of patients with ovarian cancer and other FRα expressing cancers. For the first time, the cross-functional teams we |
Sutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measuresKey Insights Given the large stake in the stock by institutions, Sutro Biopharma's stock price might be vulnerable to... |
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer- 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial - - These data confirm luvelta’s robust response rate in patients with late-stage ovarian cancer expressing a broad range of folate receptor alpha (FRα) - - Neutropenia well-managed; no new safety findings - - Luvelta is positioned for an Accelerated Approval application in mid-2027 - SOUTH SAN FRANCISCO, Calif., D |
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should KnowSutro Biopharma (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagSutro Biopharma ( NASDAQ:STRO ) Third Quarter 2024 Results Key Financial Results Revenue: US$8.52m (down 50% from 3Q... |
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue EstimatesSutro Biopharma (STRO) delivered earnings and revenue surprises of 20.27% and 53.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRαME-P1, a registration-enabling trial of luvelta for pediatric patients with rare leukemia, and REFRαME-L1, a Phase 2 trial of luvelta for patients with non-small cell lung cancer, are underway - - Sutro presented data from the Phase 1b study of luvelta in combination with bevacizumab at ESMO 2024 demonstrating a 56% response rate at |
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations at the 15th Annual World ADC Conference, taking place in San Diego, November 4-6, 2024. Presentation Details: Development of Dual-Payload Antibody Drug Conjugates Presenter: Daniel Calarese, Ph.D.Date/Time |
Sutro Biopharma begins trial of acute myeloid leukaemia treatment in childrenThe trial aims to assess Luvelta's efficacy and safety, with most of its sites due to open by the end of the year. |